semaglutide after The Pros and Cons of for Weight Loss Before and After: 5 months,

AstraZeneca - Building a strong obesity and metabolic disease pipeline Amgen - MariTide showing promising obesity treatment potential Roche - Expanding through strategic acquisitions and obesity-focused programs Pfizer - Continuing development efforts in oral obesity medicines Structure Therapeutics - Advancing next-generation oral GLP-1 candidates Viking Therapeutics - Emerging as a major obesity treatment contender Altimmune - Developing innovative metabolic disease therapies Boehringer Ingelheim - Investing in future cardiometabolic opportunities Why is everyone chasing GLP-1

Tirzepatide actually shows lower discontinuation rates due to adverse events in clinical trials

Notes: This visualization displays fee-for-service (FFS) retail pharmaceutical costs (billed on a pharmacy claim) paid by an insurance plan only

Explore Patient Assistance Programs Patient assistance programs (PAPs) offer another way to reduce costs

Hu Y, Sparks JA, Malspeis S, et al